Literature DB >> 24359787

Intragenic mutations in SMN1 may contribute more significantly to clinical severity than SMN2 copy numbers in some spinal muscular atrophy (SMA) patients.

Tomoto Yamamoto1, Hideyuki Sato2, Poh San Lai3, Dian Kesumapramudya Nurputra2, Nur Imma Fatimah Harahap2, Satoru Morikawa1, Noriyuki Nishimura1, Takashi Kurashige4, Tomohiko Ohshita4, Hideki Nakajima5, Hiroyuki Yamada6, Yoshinobu Nishida6, Soichiro Toda7, Jun-Ichi Takanashi7, Atsuko Takeuchi8, Yumi Tohyama9, Yuji Kubo10, Kayoko Saito10, Yasuhiro Takeshima11, Masafumi Matsuo12, Hisahide Nishio13.   

Abstract

BACKGROUND: Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder caused by deletion or intragenic mutation of SMN1. SMA is classified into several subtypes based on clinical severity. It has been reported that the copy number of SMN2, a highly homologous gene to SMN1, is associated with clinical severity among SMA patients with homozygous deletion of SMN1. The purpose of this study was to clarify the genotype-phenotype relationship among the patients without homozygous deletion of SMN1.
METHODS: We performed molecular genetic analyses of SMN1 and SMN2 in 112 Japanese patients diagnosed as having SMA based on the clinical findings. For the patients retaining SMN1, the PCR or RT-PCR products of SMN1 were sequenced to identify the mutation.
RESULTS: Out of the 112 patients, 106 patients were homozygous for deletion of SMN1, and six patients were compound heterozygous for deletion of one SMN1 allele and intragenic mutation in the retained SMN1 allele. Four intragenic mutations were identified in the six patients: p.Ala2Val, p.Trp92Ser, p.Thr274TyrfsX32 and p.Tyr277Cys. To the best of our knowledge, all mutations except p.Trp92Ser were novel mutations which had never been previously reported. According to our observation, clinical severity of the six patients was determined by the type and location of the mutation rather than SMN2 copy number.
CONCLUSION: SMN2 copy number is not always associated with clinical severity of SMA patients, especially SMA patients retaining one SMN1 allele.
Copyright © 2013 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Copy number; Intragenic mutation; SMN1; SMN2; Spinal muscular atrophy

Mesh:

Substances:

Year:  2013        PMID: 24359787     DOI: 10.1016/j.braindev.2013.11.009

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  11 in total

Review 1.  Advances in therapeutic development for spinal muscular atrophy.

Authors:  Matthew D Howell; Natalia N Singh; Ravindra N Singh
Journal:  Future Med Chem       Date:  2014-06       Impact factor: 3.808

2.  Gender Effects on the Clinical Phenotype in Japanese Patients with Spinal Muscular Atrophy.

Authors:  Mawaddah Ar Rochmah; Ai Shima; Nur Imma Fatimah Harahap; Emma Tabe Eko Niba; Naoya Morisada; Shinichiro Yanagisawa; Toshio Saito; Kaori Kaneko; Kayoko Saito; Ichiro Morioka; Kazumoto Iijima; Poh San Lai; Yoshihiro Bouike; Hisahide Nishio; Masakazu Shinohara
Journal:  Kobe J Med Sci       Date:  2017-10-16

3.  A new method for SMN1 and hybrid SMN gene analysis in spinal muscular atrophy using long-range PCR followed by sequencing.

Authors:  Yuji Kubo; Hisahide Nishio; Kayoko Saito
Journal:  J Hum Genet       Date:  2015-02-26       Impact factor: 3.172

4.  Intragenic variants in the SMN1 gene determine the clinical phenotype in 5q spinal muscular atrophy.

Authors:  Rodrigo de Holanda Mendonça; Ciro Matsui; Graziela Jorge Polido; André Macedo Serafim Silva; Leslie Kulikowski; Alexandre Torchio Dias; Evelin Aline Zanardo; Davi Jorge Fontoura Solla; Juliana Gurgel-Giannetti; Ana Carolina Monteiro Lessa de Moura; Gabriela Palhares Campolina Sampaio; Acary Souza Bulle Oliveira; Paulo Victor Sgobbi de Souza; Wladimir Bocca Vieira de Rezende Pinto; Eduardo Augusto Gonçalves; Igor Braga Farias; Flávia Nardes; Alexandra Prufer de Queiroz Campos Araújo; Wilson Marques; Pedro José Tomaselli; Mara Dell Ospedale Ribeiro; João Paulo Kitajima; Fabíola Paoli Monteiro; Jonas Alex Morales Saute; Michele Michelin Becker; Maria Luiza Saraiva-Pereira; Ana Carolina Brusius-Facchin; Vanessa van der Linden; Rodrigo Neves Florêncio; André Vinícius Soares Barbosa; Marcela Camara Machado-Costa; André Luiz Santos Pessoa; Leticia Silva Souza; Marcondes Cavalcante Franca; Fernando Kok; Umbertina Conti Reed; Edmar Zanoteli
Journal:  Neurol Genet       Date:  2020-09-01

5.  Phosphoethanolamine Elevation in Plasma of Spinal Muscular Atrophy Type 1 Patients.

Authors:  Mawaddah Ar Rochmah; Yogik Onky Silvana Wijaya; Nur Imma Fatimah Harahap; Chisato Tode; Atsuko Takeuchi; Kazuki Ohuchi; Masamitsu Shimazawa; Hideaki Hara; Michinori Funato; Toshio Saito; Kayoko Saito; Poh San Lai; Hiroyuki Awano; Masakazu Shinohara; Hisahide Nishio; Emma Tabe Eko Niba
Journal:  Kobe J Med Sci       Date:  2020-04-01

6.  SMA-causing missense mutations in survival motor neuron (Smn) display a wide range of phenotypes when modeled in Drosophila.

Authors:  Kavita Praveen; Ying Wen; Kelsey M Gray; John J Noto; Akash R Patlolla; Gregory D Van Duyne; A Gregory Matera
Journal:  PLoS Genet       Date:  2014-08-21       Impact factor: 5.917

7.  Alternative splicing of a cryptic exon embedded in intron 6 of SMN1 and SMN2.

Authors:  Satomi Yoshimoto; Nur Imma Fatimah Harahap; Yuko Hamamura; Mawaddah Ar Rochmah; Ai Shima; Naoya Morisada; Masakazu Shinohara; Toshio Saito; Kayoko Saito; Poh San Lai; Masafumi Matsuo; Hiroyuki Awano; Ichiro Morioka; Kazumoto Iijima; Hisahide Nishio
Journal:  Hum Genome Var       Date:  2016-12-01

Review 8.  Molecular Factors Involved in Spinal Muscular Atrophy Pathways as Possible Disease-modifying Candidates.

Authors:  Marianna A Maretina; Galina Y Zheleznyakova; Kristina M Lanko; Anna A Egorova; Vladislav S Baranov; Anton V Kiselev
Journal:  Curr Genomics       Date:  2018-08       Impact factor: 2.236

9.  Possible implication of undescribed SMN1-SMN2 genotype in chronic EMG-pattern of SMA with transitory acute denervation.

Authors:  Girolamo A Vitello; Francesco Calì; Mirella Vinci; Carmela Scuderi; Francesca L'Episcopo; Antonino Musumeci; Sebastiano A Musumeci; Antonio G Nicotera
Journal:  J Musculoskelet Neuronal Interact       Date:  2020-12-01       Impact factor: 2.041

10.  An Integrative Transcriptomic Analysis for Identifying Novel Target Genes Corresponding to Severity Spectrum in Spinal Muscular Atrophy.

Authors:  Chung-Wei Yang; Chien-Lin Chen; Wei-Chun Chou; Ho-Chen Lin; Yuh-Jyh Jong; Li-Kai Tsai; Chun-Yu Chuang
Journal:  PLoS One       Date:  2016-06-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.